Xynomic Pharmaceuticals Holdings, Inc. a biopharmaceutical company, focuses on in-licensing, developing, and commercializing oncology drug candidates in China, the United States, and internationally. The company's pipeline primarily consists of three drug candidates, abexinostat, XP-105, and XP-102. Its lead drug candidate abexinostat is in pivotal clinical trials against renal cell carcinoma (in combination with pazopanib) and non-Hodgkin's lymphoma (as a single agent). The company's other clinical stage drug candidate XP-105 (BI 860585) is a Phase 2 ready, ATP-competitive mTORC1/2 inhibitor against solid tumors; and pre-clinical oncology drug candidate XP-102 (BI 882370) is a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.
Research context
Xynomic Pharmaceuticals Holdings, Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Other
- Industry
- Other
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
No comments yet
Start a focused discussion about XYN.